[go: up one dir, main page]

HK1072361B - Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis - Google Patents

Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis Download PDF

Info

Publication number
HK1072361B
HK1072361B HK05103708.2A HK05103708A HK1072361B HK 1072361 B HK1072361 B HK 1072361B HK 05103708 A HK05103708 A HK 05103708A HK 1072361 B HK1072361 B HK 1072361B
Authority
HK
Hong Kong
Prior art keywords
treatment
dose
methyl
glucopyranosyl
patients
Prior art date
Application number
HK05103708.2A
Other languages
German (de)
English (en)
Chinese (zh)
Other versions
HK1072361A1 (en
Inventor
Ronald Gijsbertus Maria Van Amsterdam
Original Assignee
赛诺菲 安万特
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 赛诺菲 安万特 filed Critical 赛诺菲 安万特
Priority claimed from PCT/EP2003/000696 external-priority patent/WO2003063881A1/fr
Publication of HK1072361A1 publication Critical patent/HK1072361A1/en
Publication of HK1072361B publication Critical patent/HK1072361B/en

Links

Claims (4)

  1. Dose de 2,5 mg du pentasaccharide, le O-(2,3,4-tri-O-méthyl-6-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(acide 2,3-di-O-méthyl-β-D-glucopyranosyluronique)-(1→4) -O- (2,3, 6-tri-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(acide 2,3-di-O-méthyl-α-L-idopyranosyluronique)-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyle de méthyle, ou un sel pharmaceutiquement acceptable de celui-ci, destiné à une utilisation en thérapie, pour une administration une fois par semaine.
  2. Dose selon la revendication 1, caractérisée en ce que le pentasaccharide est sous forme de son sel de nonasodium (SanOrg34006).
  3. Utilisation d'une dose de 2,5 mg du pentasaccharide, le O-(2,3,4-tri-O-méthyl-6-O-sulfo-α-D-glucopyranosyl) - (1→4) -O- (acide 2,3-di-O-méthyl-β-D-glucopyranosyluronique)-(1→4)-O-(2,3,6-tri-O-sulfo-α-D-glucopyranosyl)-(1→4)-O-(acide 2,3-di-O-méthyl-α-L-idopyranosyluronique)-(1→4)-2,3,6-tri-O-sulfo-α-D-glucopyranosyle de méthyle, ou d'un sel pharmaceutiquement acceptable de celui-ci, pour la préparation d'un médicament destiné à être administré une fois par semaine pour le traitement et/ou la prophylaxie secondaire d'évènements thromboemboliques veineux chez des patients atteints de thrombose veineuse profonde.
  4. Utilisation selon la revendication 1, caractérisée en ce que le pentasaccharide est sous forme de son sel de nonasodium (SanOrg34006).
HK05103708.2A 2002-01-29 2003-01-23 Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis HK1072361B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02075374 2002-01-29
EP002075374.5 2002-01-29
PCT/EP2003/000696 WO2003063881A1 (fr) 2002-01-29 2003-01-23 Idraparinux (sanorg 34006) concu pour traiter et prevenir de maniere secondaire des evenements thromboemboliques veineux chez des patients presentant une thrombose veineuse profonde

Publications (2)

Publication Number Publication Date
HK1072361A1 HK1072361A1 (en) 2005-08-26
HK1072361B true HK1072361B (en) 2006-08-25

Family

ID=

Similar Documents

Publication Publication Date Title
Dechavanne et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery
Lindmarker et al. Comparison of once-daily subcutaneous Fragmin® with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis
JPS6218401A (ja) 結合組織病理において有効な医薬の製造に使用する多糖およびオリゴ糖
Alfaro et al. Prophylaxis of thromboembolic disease and platelet-related changes following total hip replacement: a comparative study of aspirin and heparin-dihydroergotamine
EP1471924B1 (fr) Idraparinux (sanorg 34006) concu pour traiter et prevenir de maniere secondaire des evenements thromboemboliques veineux chez des patients presentant une thrombose veineuse profonde
Buchanan et al. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II
US6391339B1 (en) Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
AU2003205664A1 (en) Idraparinux(sanorg 34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
HK1072361B (en) Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis
US20030092671A1 (en) Antithrombotic composition
Thompson‐Ford Low‐Molecular‐Weight Heparin for the Treatment of Deep Vein Thrombosis
Hyers Heparin therapy: regimens and treatment considerations
Smeets et al. Influence of low dose allopurinol on ischaemia—Reperfusion injury during abdominal aortic surgery
UA127661C2 (uk) Композиції дантролену та способи їх застосування
CN1602197A (zh) 特定剂量的Fondaparinux Sodi um在治疗急性冠状动脉综合征中的应用
Nakatani et al. The preventive effect of sodium pentosan polysulfate against renal stone formation in hyperoxaluric rats
Åberg-Wistedt et al. Lithium and renal function in relation to concomitant theory
Monreal et al. Heparins, coumarin and bone density
Nurmohamed et al. No significant accumulation of dermatan sulfate (DS) during chronic use in hemodialysis patients
de Rick et al. Clinical pharmacokinetic studies of digoxin and digitoxin in the dog
EP1321152A1 (fr) Antidote de org 31540/SR 90107A
WO1999004801A1 (fr) Utilisation de glycosaminoglycanes sulfates dans le traitement de la retinopathie
MXPA99010965A (en) Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits